

# Brit Mollenhauer

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/1647002/brit-mollenhauer-publications-by-year.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

80  
papers

5,389  
citations

35  
h-index

73  
g-index

87  
ext. papers

7,209  
ext. citations

7.4  
avg, IF

5.21  
L-index

#	Paper	IF	Citations
80	Early downregulation of hsa-miR-144-3p in serum from drug-naïve Parkinson's disease patients.. <i>Scientific Reports</i> , <b>2022</b> , 12, 1330	4.9	1
79	Detection and Quantification of Aβ-40 (APP669-711) in Cerebrospinal Fluid.. <i>Journal of Neurochemistry</i> , <b>2022</b> ,	6	1
78	Metabolite and lipoprotein profiles reveal sex-related oxidative stress imbalance in de novo drug-naïve Parkinson's disease patients.. <i>Npj Parkinsons Disease</i> , <b>2022</b> , 8, 14	9.7	1
77	Antemortem detection of Parkinson's disease pathology in peripheral biopsies using artificial intelligence.. <i>Acta Neuropathologica Communications</i> , <b>2022</b> , 10, 21	7.3	1
76	Rapid eye movement sleep behaviour disorder: Past, present, and future.. <i>Journal of Sleep Research</i> , <b>2022</b> , e13612	5.8	0
75	Evidence for immune system alterations in peripheral biological fluids in Parkinson's disease.. <i>Neurobiology of Disease</i> , <b>2022</b> , 105744	7.5	1
74	Baseline Cerebrospinal Fluid βSynuclein in Parkinson's Disease Is Associated with Disease Progression and Cognitive Decline. <i>Diagnostics</i> , <b>2022</b> , 12, 1259	3.8	
73	The relevance of synuclein autoantibodies as a biomarker for Parkinson's disease. <i>Molecular and Cellular Neurosciences</i> , <b>2022</b> , 103746	4.8	2
72	Rare PSAP Variants and Possible Interaction with GBA in REM Sleep Behavior Disorder. <i>Journal of Parkinsons Disease</i> , <b>2021</b> ,	5.3	2
71	Biomarkers of neurodegeneration and glial activation validated in Alzheimer's disease assessed in longitudinal cerebrospinal fluid samples of Parkinson's disease. <i>PLoS ONE</i> , <b>2021</b> , 16, e0257372	3.7	2
70	Preanalytical Stability of CSF Total and Oligomeric Alpha-Synuclein. <i>Frontiers in Aging Neuroscience</i> , <b>2021</b> , 13, 638718	5.3	2
69	A geroscience approach for Parkinson's disease: Conceptual framework and design of PROPAG-AGEING project. <i>Mechanisms of Ageing and Development</i> , <b>2021</b> , 194, 111426	5.6	6
68	Incidence and Progression of Rapid Eye Movement Behavior Disorder in Early Parkinson's Disease. <i>Movement Disorders Clinical Practice</i> , <b>2021</b> , 8, 534-540	2.2	3
67	Prodromal Parkinson disease - time is brain. <i>Nature Reviews Neurology</i> , <b>2021</b> , 17, 329-330	15	
66	Parkinson's Disease Subtypes: Critical Appraisal and Recommendations. <i>Journal of Parkinsons Disease</i> , <b>2021</b> , 11, 395-404	5.3	7
65	Genome-wide survival study identifies a novel synaptic locus and polygenic score for cognitive progression in Parkinson's disease. <i>Nature Genetics</i> , <b>2021</b> , 53, 787-793	36.3	15
64	Cerebrospinal βSynuclein Oligomers Reflect Disease Motor Severity in DeNoPa Longitudinal Cohort. <i>Movement Disorders</i> , <b>2021</b> , 36, 2048-2056	7	3

63	Alpha-synuclein research: defining strategic moves in the battle against Parkinson's disease. <i>Npj Parkinsons Disease</i> , <b>2021</b> , 7, 65	9.7	12
62	Comprehensive Analysis of Familial Parkinsonism Genes in Rapid-Eye-Movement Sleep Behavior Disorder. <i>Movement Disorders</i> , <b>2021</b> , 36, 235-240	7	7
61	The Mutation Matters: CSF Profiles of GCase, Sphingolipids, Ξynuclein in PD. <i>Movement Disorders</i> , <b>2021</b> , 36, 1216-1228	7	12
60	Systematic Assessment of 10 Biomarker Candidates Focusing on Ξynuclein-Related Disorders. <i>Movement Disorders</i> , <b>2021</b> ,	7	9
59	LIPAD (LRRK2/Luebeck International Parkinson's Disease) Study Protocol: Deep Phenotyping of an International Genetic Cohort. <i>Frontiers in Neurology</i> , <b>2021</b> , 12, 710572	4.1	0
58	Novel Associations of and With REM Sleep Behavior Disorder. <i>Neurology</i> , <b>2021</b> , 96, e1402-e1412	6.5	3
57	Dopamine transporter imaging predicts clinically-defined Ξynucleinopathy in REM sleep behavior disorder. <i>Annals of Clinical and Translational Neurology</i> , <b>2021</b> , 8, 201-212	5.3	6
56	Systematic characterization of human gut microbiome-secreted molecules by integrated multi-omics.. <i>ISME Communications</i> , <b>2021</b> , 1, 82		0
55	variants in REM sleep behavior disorder: A multicenter study. <i>Neurology</i> , <b>2020</b> , 95, e1008-e1016	6.5	18
54	Blood Contamination in CSF and Its Impact on Quantitative Analysis of Alpha-Synuclein. <i>Cells</i> , <b>2020</b> , 9,	7.9	16
53	Clinical and Dopamine Transporter Imaging Characteristics of Leucine Rich Repeat Kinase 2 (LRRK2) and Glucosylceramidase Beta (GBA) Parkinson's Disease Participants in the Parkinson's Progression Markers Initiative: A Cross-Sectional Study. <i>Movement Disorders</i> , <b>2020</b> , 35, 833-844	7	18
52	Fine-Mapping of SNCA in Rapid Eye Movement Sleep Behavior Disorder and Overt Synucleinopathies. <i>Annals of Neurology</i> , <b>2020</b> , 87, 584-598	9.4	24
51	Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study. <i>Lancet Neurology</i> , <i>The</i> , <b>2020</b> , 19, 71-80	24.1	37
50	Elemental fingerprint: Reassessment of a cerebrospinal fluid biomarker for Parkinson's disease. <i>Neurobiology of Disease</i> , <b>2020</b> , 134, 104677	7.5	8
49	In vivo distribution of Ξynuclein in multiple tissues and biofluids in Parkinson disease. <i>Neurology</i> , <b>2020</b> , 95, e1267-e1284	6.5	37
48	Validation of Serum Neurofilament Light Chain as a Biomarker of Parkinson's Disease Progression. <i>Movement Disorders</i> , <b>2020</b> , 35, 1999-2008	7	32
47	Feasibility and safety of lumbar puncture in the Parkinson's disease research participants: Parkinson's Progression Marker Initiative (PPMI). <i>Parkinsonism and Related Disorders</i> , <b>2019</b> , 62, 201-209	3.6	9
46	CSF and blood biomarkers for Parkinson's disease. <i>Lancet Neurology</i> , <i>The</i> , <b>2019</b> , 18, 573-586	24.1	180

45	Risk and predictors of dementia and parkinsonism in idiopathic REM sleep behaviour disorder: a multicentre study. <i>Brain</i> , <b>2019</b> , 142, 744-759	11.2	303
44	Antibody-based methods for the measurement of $\beta$ synuclein concentration in human cerebrospinal fluid - method comparison and round robin study. <i>Journal of Neurochemistry</i> , <b>2019</b> , 149, 126-138	6	26
43	Longitudinal analyses of cerebrospinal fluid $\beta$ synuclein in prodromal and early Parkinson's disease. <i>Movement Disorders</i> , <b>2019</b> , 34, 1354-1364	7	48
42	Parkinson's disease biomarkers based on $\beta$ synuclein. <i>Journal of Neurochemistry</i> , <b>2019</b> , 150, 626-636	6	46
41	Cerebrospinal fluid biomarker for Parkinson's disease: An overview. <i>Molecular and Cellular Neurosciences</i> , <b>2019</b> , 97, 60-66	4.8	22
40	Baseline predictors for progression 4 years after Parkinson's disease diagnosis in the De Novo Parkinson Cohort (DeNoPa). <i>Movement Disorders</i> , <b>2019</b> , 34, 67-77	7	74
39	Longitudinal Change of Clinical and Biological Measures in Early Parkinson's Disease: Parkinson's Progression Markers Initiative Cohort. <i>Movement Disorders</i> , <b>2018</b> , 33, 771-782	7	73
38	The importance of an independent validation cohort for metabolomics biomarker studies. <i>Movement Disorders</i> , <b>2018</b> , 33, 856	7	4
37	The Parkinson's progression markers initiative (PPMI) - establishing a PD biomarker cohort. <i>Annals of Clinical and Translational Neurology</i> , <b>2018</b> , 5, 1460-1477	5.3	142
36	The depressed brain in Parkinson's disease: Implications for an inflammatory biomarker. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2017</b> , 114, 3004-3005	11.5	5
35	Development of a Biochemical Diagnosis of Parkinson Disease by Detection of $\beta$ synuclein Misfolded Aggregates in Cerebrospinal Fluid. <i>JAMA Neurology</i> , <b>2017</b> , 74, 163-172	17.2	202
34	Longitudinal CSF biomarkers in patients with early Parkinson disease and healthy controls. <i>Neurology</i> , <b>2017</b> , 89, 1959-1969	6.5	84
33	Candidate inflammatory biomarkers display unique relationships with alpha-synuclein and correlate with measures of disease severity in subjects with Parkinson's disease. <i>Journal of Neuroinflammation</i> , <b>2017</b> , 14, 164	10.1	34
32	Distinct metabolomic signature in cerebrospinal fluid in early parkinson's disease. <i>Movement Disorders</i> , <b>2017</b> , 32, 1401-1408	7	53
31	A user's guide for $\beta$ synuclein biomarker studies in biological fluids: Perianalytical considerations. <i>Movement Disorders</i> , <b>2017</b> , 32, 1117-1130	7	35
30	Acute Levodopa Challenge Test in Patients with de novo Parkinson's Disease: Data from the DeNoPa Cohort. <i>Movement Disorders Clinical Practice</i> , <b>2017</b> , 4, 755-762	2.2	18
29	Evaluation of $\beta$ synuclein as a novel cerebrospinal fluid biomarker in different forms of prion diseases. <i>Alzheimers and Dementia</i> , <b>2017</b> , 13, 710-719	1.2	38
28	The utility of $\beta$ synuclein as biofluid marker in neurodegenerative diseases: a systematic review of the literature. <i>Biomarkers in Medicine</i> , <b>2016</b> , 10, 19-34	2.3	67

27	Cerebrospinal $\beta$ synuclein in $\beta$ synuclein aggregation disorders: tau/ $\beta$ synuclein ratio as potential biomarker for dementia with Lewy bodies. <i>Journal of Neurology</i> , <b>2016</b> , 263, 2271-2277	5.5	27
26	Induction of $\beta$ synuclein aggregate formation by CSF exosomes from patients with Parkinson's disease and dementia with Lewy bodies. <i>Brain</i> , <b>2016</b> , 139, 481-94	11.2	251
25	Biological confounders for the values of cerebrospinal fluid proteins in Parkinson's disease and related disorders. <i>Journal of Neurochemistry</i> , <b>2016</b> , 139 Suppl 1, 290-317	6	45
24	CSF biomarkers associated with disease heterogeneity in early Parkinson's disease: the Parkinson's Progression Markers Initiative study. <i>Acta Neuropathologica</i> , <b>2016</b> , 131, 935-49	14.3	138
23	The Evolution of REM Sleep Behavior Disorder in Early Parkinson Disease. <i>Sleep</i> , <b>2016</b> , 39, 1737-42	1.1	63
22	Monitoring of 30 marker candidates in early Parkinson disease as progression markers. <i>Neurology</i> , <b>2016</b> , 87, 168-77	6.5	104
21	Multicenter immunoassay validation of cerebrospinal fluid neurofilament light: a biomarker for neurodegeneration. <i>Bioanalysis</i> , <b>2016</b> , 8, 2243-2254	2.1	10
20	Validation of conversion between mini-mental state examination and montreal cognitive assessment. <i>Movement Disorders</i> , <b>2016</b> , 31, 593-6	7	37
19	Validation of a quantitative cerebrospinal fluid alpha-synuclein assay in a European-wide interlaboratory study. <i>Neurobiology of Aging</i> , <b>2015</b> , 36, 2587-96	5.6	29
18	Cerebrospinal fluid biomarkers in trials for Alzheimer and Parkinson diseases. <i>Nature Reviews Neurology</i> , <b>2015</b> , 11, 41-55	15	116
17	Quantification of $\beta$ synuclein in cerebrospinal fluid: how ideal is this biomarker for Parkinson's disease?. <i>Parkinsonism and Related Disorders</i> , <b>2014</b> , 20 Suppl 1, S76-9	3.6	29
16	Association of cerebrospinal fluid $\beta$ amyloid 1-42, T-tau, P-tau181, and $\beta$ synuclein levels with clinical features of drug-naive patients with early Parkinson disease. <i>JAMA Neurology</i> , <b>2013</b> , 70, 1277-87	17.2	252
15	Total CSF $\beta$ synuclein is lower in de novo Parkinson patients than in healthy subjects. <i>Neuroscience Letters</i> , <b>2013</b> , 532, 44-8	3.3	103
14	Nonmotor and diagnostic findings in subjects with de novo Parkinson disease of the DeNoPa cohort. <i>Neurology</i> , <b>2013</b> , 81, 1226-34	6.5	122
13	Unrecognized vitamin D3 deficiency is common in Parkinson disease: Harvard Biomarker Study. <i>Neurology</i> , <b>2013</b> , 81, 1531-7	6.5	83
12	Recommendations to standardize preanalytical confounding factors in Alzheimer's and Parkinson's disease cerebrospinal fluid biomarkers: an update. <i>Biomarkers in Medicine</i> , <b>2012</b> , 6, 419-30	2.3	230
11	$\beta$ synuclein in human cerebrospinal fluid is principally derived from neurons of the central nervous system. <i>Journal of Neural Transmission</i> , <b>2012</b> , 119, 739-46	4.3	56
10	The Parkinson Progression Marker Initiative (PPMI). <i>Progress in Neurobiology</i> , <b>2011</b> , 95, 629-35	10.9	793

9	βSynuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study. <i>Lancet Neurology, The</i> , <b>2011</b> , 10, 230-40	24.1	459
8	Quantification of βsynuclein in cerebrospinal fluid as a biomarker candidate: review of the literature and considerations for future studies. <i>Biomarkers in Medicine</i> , <b>2010</b> , 4, 683-99	2.3	101
7	Direct quantification of CSF alpha-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration. <i>Experimental Neurology</i> , <b>2008</b> , 213, 315-25	5.7	282
6	GATA transcription factors directly regulate the Parkinson's disease-linked gene alpha-synuclein. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2008</b> , 105, 10907-12	11.5	205
5	Serum heart-type fatty acid-binding protein and cerebrospinal fluid tau: marker candidates for dementia with Lewy bodies. <i>Neurodegenerative Diseases</i> , <b>2007</b> , 4, 366-75	2.3	55
4	Total tau protein, phosphorylated tau (181p) protein, beta-amyloid(1-42), and beta-amyloid(1-40) in cerebrospinal fluid of patients with dementia with Lewy bodies. <i>Clinical Chemistry and Laboratory Medicine</i> , <b>2006</b> , 44, 192-5	5.9	45
3	Validation of Serum Neurofilament Light Chain as a Biomarker of Parkinson's Disease Progression		2
2	A nanobody-based fluorescent reporter reveals human βsynuclein in the cell cytosol		1
1	Genome-wide association study of REM sleep behavior disorder identifies novel loci with distinct polygenic and brain expression effects		1